Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US BioDefense makes cardiac regeneration pact:

This article was originally published in Clinica

Executive Summary

US BioDefense has formed a heart tissue regeneration deal with the University of Texas MD Anderson Cancer Center that gives it the priority option to review and license patent pending technology regarding the use of non-marrow stem cell for cardiac regeneration. "The use of these stem cells for myocardial regeneration may prove to be superior to other stem cell sources by circumventing the pain and anaesthesia complications associated with bone marrow aspiration procedures," said David Chin, CEO of the City of Industry, California-based firm.

You may also be interested in...



PBA Announces New Leadership; Honest Company Names CFO; Beauty Executive News

Nina Daily, chief marketing officer at the Professional Beauty Association since July 2018, will succeed Steve Sleeper as executive director at the end of June when Sleeper retires. More cosmetics industry appointments.

Biden Aims For 200 Mil. More COVID Vaccine Doses As Nervous Europe Eyes Its Borders

Third round of orders would give the US all the vaccine it needs from the existing mRNA products, taking pressure off AstraZeneca is it experiences manufacturing challenges and the EU considers export restrictions to ensure it gets enough vaccine.

Listerine, Tylenol Push J&J Consumer Health To 2020 Finish Line Against Pandemic Weight

Listerine mouthwash drove J&J’s oral care sales up 11.4% in the fourth quarter. Tylenol for adults was the star of its OTC drug business but weakness of children’s Tylenol products and other OTCs led to flat sales.

Topics

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel